Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Long-Term Deferred Tax (2020 - 2025)

Catalyst Pharmaceuticals (CPRX) has disclosed Long-Term Deferred Tax for 9 consecutive years, with $52.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 14.76% year-over-year to $52.8 million, compared with a TTM value of $52.8 million through Dec 2025, up 14.76%, and an annual FY2025 reading of $52.8 million, up 14.76% over the prior year.
  • Long-Term Deferred Tax was $52.8 million for Q4 2025 at Catalyst Pharmaceuticals, up from $48.3 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $52.8 million in Q4 2025 and bottomed at $18.7 million in Q4 2022.
  • Average Long-Term Deferred Tax over 5 years is $34.1 million, with a median of $34.0 million recorded in 2021.
  • The sharpest move saw Long-Term Deferred Tax plummeted 30.33% in 2022, then surged 95.05% in 2023.
  • Year by year, Long-Term Deferred Tax stood at $23.7 million in 2021, then fell by 20.94% to $18.7 million in 2022, then soared by 95.05% to $36.5 million in 2023, then rose by 25.83% to $46.0 million in 2024, then grew by 14.76% to $52.8 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for CPRX at $52.8 million in Q4 2025, $48.3 million in Q3 2025, and $50.7 million in Q2 2025.